Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
复制标题
ErbB家族靶向疗法在骨肉瘤治疗中的进展
DOI：
10.1007/s10637-018-0684-8
复制
发表时间：
2018-10
影响因子：
3.4
通讯作者：
Gong H
中科院分区：
文献类型：
--
作者：
Wang W;Zhao HF;Yao TF;Gong H
骨肉瘤（osteosarcoma，OS）是最常见的原发性侵袭性恶性骨肿瘤。新诊断的OS患者受益于标准治疗，包括手术切除加放疗和新辅助化疗（MAP化疗：高剂量甲氨蝶呤、多柔比星和顺铂）。然而，肿瘤复发和转移导致OS患者的5年总生存率急剧下降。几十年来几乎没有什么进展，这促使人们开发更有效的治疗方法。ErbB受体家族包括EGFR、HER 2、HER 3和HER 4，对PI 3 K/Akt和MAPK信号通路的激活起重要作用，是OS治疗的潜在靶点。ErbB的基因畸变（扩增、过表达、突变和剪接改变）对多种癌症的生长、凋亡、运动和转移是必不可少的。ErbB家族的过度表达与癌症患者的不良预后相关。许多ErbB家族特异性单克隆抗体或抑制剂已进入临床试验，用于治疗包括乳腺癌、肺癌和肉瘤在内的一系列实体瘤。本文就ErbB家族在OS中的作用、表达以及以ErbB为靶点的治疗策略（包括化疗和免疫治疗）的研究进展进行综述。
Osteosarcoma (OS) is the most common primary aggressive and malignant bone tumor. Newly diagnostic OS patients benefit from the standard therapy including surgical resection plus radiotherapy and neoadjuvant chemotherapy (MAP chemotherapy: high-dose methotrexate, doxorubicin and cisplatin). However, tumor recurrence and metastasis give rise to a sharp decline of the 5-year overall survival rate in OS patients. Little improvement has been made for decades, urging the development of more effective therapeutic approaches. ErbB receptor family including EGFR, HER2, HER3 and HER4, being important to the activation of PI3K/Akt and MAPK signaling pathways, are potential targets for OS treatment. Genetic aberrations (amplification, overexpression, mutation and altered splicing) of ErbB are essential to the growth, apoptosis, motility and metastasis in a variety of cancers. Overexpression of ErbB family is associated with the poor prognosis of cancer patients. A number of monoclonal antibodies or inhibitors specific for ErbB family have entered clinical trials in a range of solid tumors including breast carcinoma, lung carcinoma and sarcoma. Here, we summarized the roles and expression of ErbB family in OS and the current development of ErbB-targeted therapeutic strategies including chemotherapies and immunotherapies for OS treatment.
登录
查看更多内容
DOI：
10.1016/s1077-9108(08)79091-1
发表时间：
2009
期刊：
Yearbook of Pathology and Laboratory Medicine
影响因子：
--
作者：
F.A.M. Bordonaba
通讯作者：
F.A.M. Bordonaba
影响因子：
2.9
作者：
Kumagai T;Tomita Y;Nakatsuka SI;Kimura M;Kunimasa K;Inoue T;Tamiya M;Nishino K;Susaki Y;Kusu T;Tokunaga T;Okami J;Higashiyama M;Imamura F
通讯作者：
Imamura F
影响因子：
11.5
作者：
Pahl, Jens H. W.;Ruslan, S. Eriaty N.;Lankester, Arjan C.
通讯作者：
Lankester, Arjan C.
影响因子：
16.6
作者：
Behjati S;Tarpey PS;Haase K;Ye H;Young MD;Alexandrov LB;Farndon SJ;Collord G;Wedge DC;Martincorena I;Cooke SL;Davies H;Mifsud W;Lidgren M;Martin S;Latimer C;Maddison M;Butler AP;Teague JW;Pillay N;Shlien A;McDermott U;Futreal PA;Baumhoer D;Zaikova O;Bjerkehagen B;Myklebost O;Amary MF;Tirabosco R;Van Loo P;Stratton MR;Flanagan AM;Campbell PJ
通讯作者：
Campbell PJ
DOI：
10.1186/s13046-015-0251-5
发表时间：
2015-11-02
期刊：
Journal of experimental & clinical cancer research : CR
影响因子：
--
作者：
Sevelda F;Mayr L;Kubista B;Lötsch D;van Schoonhoven S;Windhager R;Pirker C;Micksche M;Berger W
通讯作者：
Berger W